What does Editas Medicine, Inc. do?
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL…
What is Editas Medicine, Inc.'s P/E and P/B ratio?
Editas Medicine, Inc. has a P/E ratio of -3.7 and a P/B ratio of 3.63.
What is Editas Medicine, Inc.'s debt-to-equity ratio?
Editas Medicine, Inc. has a debt-to-equity ratio of 0.15.
How much does Editas Medicine, Inc. owe compared with what it owns?
Editas Medicine, Inc. owes $0.56 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Editas Medicine, Inc.'s Positivity rank?
Editas Medicine, Inc. is ranked #4,959 of 6,774 companies globally and #2,611 of 4,000 in United States on PositoAI, with a Positivity Score of 18,680.
Does Editas Medicine, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Editas Medicine, Inc. has no active red flags. It has 1 yellow flag (PosiYellow stress signals, 2/10 points): Change of auditor (8-K Item 4.01).
Where can I read the latest news about Editas Medicine, Inc.?
Recent headlines about Editas Medicine, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Editas Medicine, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Editas Medicine, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.